In patients with RLC > 13 % ( n = 159 : catumaxomab , 100 and control , 59 ) , catumaxomab was associated with a favorable effect on OS versus paracentesis alone ( P = 0.0072 ) , with a median/mean OS benefit of 41/131 days and an increased 6-month survival rate of 37.0 % versus 5.2 % , respectively .